Status report of lipid-lowering trials in diabetes

被引：10

作者：

Betteridge, DJ

Colhoun, H

Armitage, J

机构：

[1] UCL, Dept Med, London, England

[2] UCL, Dept Epidemiol & Publ Hlth Med, London, England

[3] Radcliffe Infirm, Clin Trials Serv Unit, Oxford OX2 6HE, England

来源：

CURRENT OPINION IN LIPIDOLOGY | 2000年 / 11卷 / 06期

关键词：

D O I：

10.1097/00041433-200012000-00009

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes. Diabetic dyslipidaemia is an important risk factor and is open to therapeutic intervention. However, as yet there are no primary or secondary coronary heart disease prevention trials of lipid-lowering therapy reported in diabetic populations. In this review, on-going clinical trials of lipid-lowering therapy in specific diabetic populations will be described. Curr Opin Lipidol 11:621-626. (C) 2000 Lippincott Williams & Wilkins.

引用

页码：621 / 626

页数：6

共 35 条

[1]

Alderman EL, 1996, NEW ENGL J MED, V335, P217

[2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[3]

*AM DIAB ASS, 1999, DIABETES CARE S1, V22, pS56

[4] Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials [J].

Armitage, J ;

Collins, R .

HEART, 2000, 84 (04) :357-360

[5] Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction [J].

Aronson, D ;

Rayfield, EJ ;

Chesebro, JH .

ANNALS OF INTERNAL MEDICINE, 1997, 126 (04) :296-306

[6] WHY IS DIABETES-MELLITUS A STRONGER RISK FACTOR FOR FATAL ISCHEMIC-HEART-DISEASE IN WOMEN THAN IN MEN - THE RANCHO-BERNARDO STUDY [J].

BARRETTCONNOR, EL ;

COHN, BA ;

WINGARD, DL ;

EDELSTEIN, SL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (05) :627-631

[7] ATHEROGENESIS IN DIABETES [J].

BIERMAN, EL .

ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (06) :647-656

[8] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].

Downs, JR ;

Clearfield, M ;

Weis, S ;

Whitney, E ;

Shapiro, DR ;

Beere, PA ;

Langendorfer, A ;

Stein, EA ;

Kruyer, W ;

Gotto, AM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622

[9]

Gerstein HC, 2000, LANCET, V355, P253

[10] Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels -: Subgroup analyses in the cholesterol and recurrent events (CARE) trial [J].

Goldberg, RB ;

Mellies, MJ ;

Sacks, FM ;

Moyé, LA ;

Howard, BV ;

Howard, WJ ;

Davis, BR ;

Cole, TG ;

Pfeffer, MA ;

Braunwald, E .

CIRCULATION, 1998, 98 (23) :2513-2519

← 1 2 3 4 →